Vagus nerve stimulation in treating depression: A tale of two stories.

Author(s): T.-F. Yuan, A. Li, X. Sun, O. Arias-Carrión, S. Machado

Journal Name: Current Molecular Medicine

Volume 16 , Issue 1 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Vagus nerve stimulation (VNS) has been widely used to treat different neurological disorders, especially epilepsy. Accumulating evidence also suggests its potential application in antidepressive therapy, given that VNS has been confirmed by several clinical trials to exert long-term effects on mitigating depression and reducing the risk of relapse in depressed patients. Likewise, VNS has also proven to ameliorate the behavioral deficits in a rat model of depression. While the influences of VNS on monoamine metabolism and mood improvement are well-recognized, the underlying mechanisms mediating its antidepressive action remain poorly understood. Recent findings suggest that VNS-enhanced proliferation of hippocampal neural progenitor cells (NPCs) and synaptic transmission might serve as a monoamine-independent pathway contributive to the beneficial effects of VNS on depression. Here we briefly reviewed the recent progress in this field, based on which we propose that there might be, at least, two little-overlapped, and yet interactive pathways mediating the antidepressive action of VNS.

Keywords: Vagus nerve stimulation, depression, neurogenesis, hippocampus, monoamine, brain-derived neurotrophic factor.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 08 January, 2016
Page: [33 - 39]
Pages: 7
DOI: 10.2174/1566524016666151222143609
Price: $65

Article Metrics

PDF: 35
PRC: 1